Integrated analyses of multi-omic data derived from paired primary lung cancer and brain metastasis reveal the metabolic vulnerability as a novel therapeutic target

Hao Duan,Jianlan Ren,Shiyou Wei,Zhenyu Yang,Chuan Li,Zhenning Wang,Meichen Li,Zhi Wei,Yu Liu,Xiuqi Wang,Hongbin Lan,Zhen Zeng,Maodi Xie,Yuan Xie,Suwen Wu,Wanming Hu,Chengcheng Guo,Xiangheng Zhang,Lun Liang,Chengwei Yu,Yanhao Mou,Yu Jiang,Houde Li,Eric Sugarman,Rebecca A. Deek,Zexin Chen,Tao Li,Yaohui Chen,Maojin Yao,Likun Chen,Lunxu Liu,Gao Zhang,Yonggao Mou
DOI: https://doi.org/10.1186/s13073-024-01410-8
IF: 15.266
2024-11-28
Genome Medicine
Abstract:Lung cancer brain metastases (LC-BrMs) are frequently associated with dismal mortality rates in patients with lung cancer; however, standard of care therapies for LC-BrMs are still limited in their efficacy. A deep understanding of molecular mechanisms and tumor microenvironment of LC-BrMs will provide us with new insights into developing novel therapeutics for treating patients with LC-BrMs.
genetics & heredity
What problem does this paper attempt to address?